Novel antipsychotic drugs

著者

書誌事項

Novel antipsychotic drugs

editor, Herbert Y. Meltzer

Raven Press, c1992

大学図書館所蔵 件 / 全2件

この図書・雑誌をさがす

注記

Includes bibliographical references and index

内容説明・目次

内容説明

This volume contains the highlights of an American College of Neuropsychopharmacology conference on new directions in the development of a typical and other novel antipsychotic drugs. An international group of psychiatrists from leading medical centres and researchers from universities and the pharmaceutical industry presents new theories and preclinical and clinical data on various drugs and classes of drugs, including amperozide and other clozapine-type drugs, substituted benzamides, dopamine partial agonists, dopamine autoreceptor agonists. D1, D3 and D4 antagonists, milacemide, glycine, sigma antagonists, and 5-HT3 antagonists. The contributors develop concepts on the receptor selectivities and mechanisms of action of a typical neuroleptics and identify various receptors and neurochemical mechanisms as new targets for antipsychotic drugs. The book includes a clinical overview of risperidone and discussions on the pattern of efficacy of clozapine in treatment resistant schizophrenia, the mechanism of action of clozapine in relation to its clinical advantages, and the efficacy and tolerability of novel dopamine agonists.

目次

  • Part 1 Clozapine type atypical antipsychotic drugs: the mechanism of action of clozapine in relation to its clinical advantages, Herbert Y. Meltzer
  • Org 5222 - preliminary clinical results, J.M. Ad Sitsen and Maria C. Vrijmoed-de Vries
  • amperozide and some other atypical compounds with antipsychotic effect, Erick G.G. Christensson
  • clozapine - pattern of efficacy in treatment-resistant schizophrenia, Herbert Y. Meltzer
  • amperozide in the treatment of schizophrenic patients - a preliminary report, Anders Bjork, et al. Part 2 Substituted benzamides: comparison of the effects of different substituted benzamides on depamine receptor function in the rat, Sven O. Ogren and M. Hall
  • remoxipride and raclopride - pharmacological background and clinical outcome, Tommy Lewander, et al. Part 3 Dopamine agonists: effects of PD 128483, a novel dopamine autoreceptor agonist, in preclinical antipsychotic tests, Thomas G. Heffner, et al
  • novel dopamine autoreceptor agonists B-HT 920 and EMD 49980 in the treatment of patients with schizophrenia, Klaus Wiedemann, et al
  • efficacy and tolerability of SDZ HDC 912, a partial dopamine D2 agonist, in the treatment of schizophrenia, Dieter Naber, et al
  • the status of "Second Generation" selective D. dopamine receptor antagonists as putative atypical antipsychotics, John L. Waddington and Siobhan A. Daly
  • toward the understanding of the neuroanatomical substrate of schizophrenia - the contribution of savoxepine, Serge F. Bischoff
  • the dopamine D3 receptor as a target for antipsychotics, Jean-Charles Schwartz, et al
  • receptor selectivities of a typical neuroleptics, Philip Seeman. Part 4 Other approaches: glutamatergic mechanisms in neuropsychiatry, John W. Olney
  • enhancement of NMDA-mediated transmission in schizophrenia - effects of milacemide, Carol A. Tamminga, et al
  • glycine in the treatment of schizophrenia - theory and preliminary results, Steven G. Potkin, et al
  • sigma "antagonists" - potential antipsychotics?, Duncan P. Taylor and R. Francis Schelemmer, Jr
  • clinical efficacy of sigma antagonists in schizophrenia, Richard L. Borison, et al
  • antipsychotic potential of 5-Ht3 antagonists in schizophrenia, Richard L. Borison, et al
  • antipsychotic potential of 5-HT3 antagonists - preclinical data, Michael G. Palfreyman, et al
  • the effects of a novel 5-HT3 antagonist, ondansetron, in schizophrenia - results from uncontrolled trials, Joseph DeVeaugh-Geiss, et al
  • clinical overview of resperidone, Richard L. Borison, et al
  • what makes a neuroleptic atypical, Daniel E. Casey.

「Nielsen BookData」 より

詳細情報

ページトップへ